Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Nasdaq 100 Movers: GILD, EA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 10:36am EST

In early trading on Tuesday, shares of Electronic Arts (EA) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.8%. Year to date, Electronic Arts registers a 27.9% gain.

And the worst performing Nasdaq 100 component thus far on the day is Gilead Sciences (GILD), trading down 4.6%. Gilead Sciences is showing a gain of 3.2% looking at the year to date performance.

Two other components making moves today are Take-Two Interactive Software (TTWO), trading down 4.3%, and JD. om (JD), trading up 3.6% on the day.

© BNK Invest, source Videos

Stocks mentioned in the article
ChangeLast1st jan.
ELECTRONIC ARTS 1.51% 106.84 Delayed Quote.35.39%
GILEAD SCIENCES 1.84% 67.59 Delayed Quote.8.06%
TAKE-TWO INTERACTIVE SOFTWARE 0.02% 93.3 Delayed Quote.-9.36%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
02/14GILEAD SCIENCES : Stock Slides Lower on NASH Drug Failure
AQ
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/12Coty and Electronic Arts surge while Molson Coors dips
AQ
02/12GILEAD SCIENCES : Announces Topline Data from Phase 3 STELLAR-4 Study of Selonse..
AQ
02/11GILEAD SCIENCES : Announces Topline Data From Phase 3 STELLAR-4 Study of Selonse..
BU
02/08GILEAD SCIENCES : Report
CO
02/05GILEAD SCIENCES : Ralph Lauren surges, Gilead sinks
AQ
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Updat..
DJ
02/04GILEAD SCIENCES : Raises Dividend by 6 Cents a Share
DJ
02/04GILEAD : 4Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2019 21 974 M
EBIT 2019 11 241 M
Net income 2019 6 595 M
Debt 2019 6 341 M
Yield 2019 3,74%
P/E ratio 2019 13,16
P/E ratio 2020 11,87
EV / Sales 2019 4,27x
EV / Sales 2020 3,70x
Capitalization 87 436 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,7 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES8.06%87 436
VERTEX PHARMACEUTICALS13.49%48 081
REGENERON PHARMACEUTICALS13.51%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252
NEUROCRINE BIOSCIENCES, INC.18.08%7 658